Gsk (GSK) EPS (Basic) Growth (3y) (2012 - 2026)
Gsk (GSK) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | -34.06% |
| 10 | Sanofi | 55.24 Bn | 47.86 Bn | 10.79 Bn | -35.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.06% |
| Mar 31, 2026 | 8.88% |
| Dec 31, 2025 | -38.63% |
| Sep 30, 2025 | -40.65% |
| Jun 30, 2025 | 21.44% |
| Mar 31, 2025 | -6.01% |
| Dec 31, 2024 | -5.63% |
| Sep 30, 2024 | -26.95% |
| Jun 30, 2024 | -9.43% |
| Mar 31, 2024 | 5.62% |
| Dec 31, 2023 | -9.10% |
| Sep 30, 2023 | -27.92% |
| Jun 30, 2023 | -10.88% |
| Mar 31, 2023 | -4.04% |
| Dec 31, 2022 | 95.54% |
| Sep 30, 2022 | 87.05% |
| Jun 30, 2022 | -5.80% |
| Mar 31, 2022 | 30.02% |
| Dec 31, 2021 | -11.17% |
| Sep 30, 2021 | -5.07% |